Practical Liposomal Formulation for Taxanes with Polyethoxylated Castor Oil and Ethanol with Complete Encapsulation Efficiency and High Loading Efficiency

Taxanes including paclitaxel and docetaxel are effective anticancer agents preferably sufficient for liposomal drug delivery. However, the encapsulation of these drugs with effective amounts into conventional liposomes is difficult due to their high hydrophobicity. Therefore, an effective encapsulation strategy for liposomal taxanes has been eagerly anticipated. In this study, the mixture of polyethoxylated castor oil (Cremophor EL) and ethanol containing phosphate buffered saline termed as CEP was employed as a solvent of the inner hydrophilic core of liposomes where taxanes should be incorporated. Docetaxel-, paclitaxel-, or 7-oxacetylglycosylated paclitaxel-encapsulating liposomes were successfully prepared with almost 100% of encapsulation efficiency and 29.9, 15.4, or 29.1 mol% of loading efficiency, respectively. We then applied the docetaxel-encapsulating liposomes for targeted drug delivery. Docetaxel-encapsulating liposomes were successfully developed HER2-targeted drug delivery by coupling HER2-specific binding peptide on liposome surface. The HER2-targeting liposomes exhibited HER2-specific internalization and enhanced anticancer activity in vitro. Therefore, we propose the sophisticated preparation of liposomal taxanes using CEP as a promising formulation for effective cancer therapies.

[1]  Wahid Khan,et al.  Liposomal Formulations in Clinical Use: An Updated Review , 2017, Pharmaceutics.

[2]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[3]  V. Adam,et al.  Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes , 2016, Scientific Reports.

[4]  D. Salomon,et al.  Evaluation of glycosylated docetaxel-encapsulated liposomes prepared by remote loading under solubility gradient , 2016, Journal of microencapsulation.

[5]  Soon-Seok Hong,et al.  Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. , 2015, International journal of pharmaceutics.

[6]  V. Adam,et al.  Modulation of Induced Cytotoxicity of Doxorubicin by Using Apoferritin and Liposomal Cages , 2014, International journal of molecular sciences.

[7]  D. Salomon,et al.  Efficient Drug Delivery of Paclitaxel Glycoside: A Novel Solubility Gradient Encapsulation into Liposomes Coupled with Immunoliposomes Preparation , 2014, PloS one.

[8]  Peeyush N. Goel,et al.  Anti-neuropilin 1 antibody Fab′ fragment conjugated liposomal docetaxel for active targeting of tumours , 2014, Journal of drug targeting.

[9]  D. Salomon,et al.  Identification of Caveolin-1 as a Potential Causative Factor in the Generation of Trastuzumab Resistance in Breast Cancer Cells , 2013, Journal of Cancer.

[10]  Jaroslav Turánek,et al.  Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Seno,et al.  Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand , 2011, Journal of cellular and molecular medicine.

[13]  Kazuo Maruyama,et al.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. , 2011, Advanced drug delivery reviews.

[14]  Hsiang-Fa Liang,et al.  A Liposomal Formulation Able to Incorporate a High Content of Paclitaxel and Exert Promising Anticancer Effect , 2010, Journal of drug delivery.

[15]  D. Salomon,et al.  Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. , 2010, International journal of pharmaceutics.

[16]  J. Turánek,et al.  Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect. , 2010, Journal of pharmaceutical sciences.

[17]  Leaf Huang,et al.  Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. , 2009, Biochimica et biophysica acta.

[18]  H. Shmeeda,et al.  Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[19]  T. Yang,et al.  Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells , 2007, Pharmaceutical Research.

[20]  A. Martin,et al.  Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines , 2007, Cell proliferation.

[21]  Dae-Duk Kim,et al.  Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Dae-Duk Kim,et al.  Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. , 2007, International journal of pharmaceutics.

[23]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Hong Liu,et al.  Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel. , 2005, World journal of gastroenterology.

[25]  F. Sarkar,et al.  Epidermal growth factor receptor (EGFR)–related protein inhibits multiple members of the EGFR family in colon and breast cancer cells , 2005, Molecular Cancer Therapeutics.

[26]  D. Weaver,et al.  Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells , 2004, International journal of cancer.

[27]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[28]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[29]  K. Hara,et al.  Synthesis and Biological Evaluation of Water Soluble Taxoids Bearing Sugar Moieties , 2001 .

[30]  F. Dosio,et al.  Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[31]  P. Cullis,et al.  Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. , 1998, Biochimica et biophysica acta.

[32]  Lawrence Mayer,et al.  Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel , 1997, Anti-cancer drugs.

[33]  E. Moase,et al.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.

[34]  Philip R. Cohen,et al.  The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). , 1993, Cancer treatment reviews.

[35]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[36]  M. D’Incalci,et al.  Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[38]  山本 祐司 Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts , 2011 .

[39]  M. Bissery,et al.  Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®) , 2007, Investigational New Drugs.

[40]  T. Andresen,et al.  Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.

[41]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.